Byondis

Byondis Announces Positive Topline Results of Pivotal Phase III TULIP Study in Patients with HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Byondis B.V. today announced positive topline results from the Phase III TULIP study, a multi-center, open-label, randomized clinical trial.
Byondis B.V. Microweg 22 P.O. Box 6570 6503 GB Nijmegen, the Netherlands

+31 (0)24 679 5100